Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
Authors:
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (8) , 1306-1316
Abstract
No abstract availableKeywords
Funding Information
- Merck KGaA
- Pfizer
This publication has 19 references indexed in Scilit:
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung CancerJAMA Oncology, 2017
- Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung CancerClinical Cancer Research, 2017
- Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor responseBiomarker Research, 2017
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectJournal of Thoracic Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1Archives of Pathology & Laboratory Medicine, 2016
- Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint InhibitorCancer Immunology Research, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor CellsCancer Immunology Research, 2015
- A Confidence Interval for the Median Survival Time1982